Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor

被引:235
作者
Sheskin, T
Hanus, L
Slager, J
Vogel, Z
Mechoulam, R
机构
[1] HEBREW UNIV JERUSALEM,FAC MED,DEPT NAT PROD,IL-91120 JERUSALEM,ISRAEL
[2] WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL
关键词
D O I
10.1021/jm960752x
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In order to establish the structural requirements for binding to the brain cannabinoid receptor (CB1), we have synthesized numerous fatty acid amides, ethanolamides, and some related simple derivatives and have determined their K-i values. A few alpha-methyl- or alpha,alpha-dimethylarachidonoylalkylamides were also examined. In the 20:4, n-6 series, the unsubstituted amide is inactive; N-monoalkylation, at least up to a branched pentyl group, leads to significant binding. N,N-Dialkylation, with or without hydroxylation on one of the alkyl groups, leads to elimination of activity. Hydroxylation of the N-monoalkyl group at the omega carbon atom retains activity. In the 20:x, n-6 series, x has to be either 3 or 4; the presence of only two double bonds leads to inactivation. In the n-3 series, the limited data reported suggest that the derived ethanolamides are either inactive or less active than comparable compounds in the n-6 series. Alkylation or dialkylation of the alpha carbon adjacent to the carbonyl group retains the level of binding in the case of anandamide (compounds 48, 49); however, alpha-monomethylation or alpha,alpha-dimethylation of N-propyl derivatives (50-53) potentiates binding and leads to the most active compounds seen in the present work (K-i values of 6.9 +/- 0.7 to 8.4 +/- 1.1 nM). We have confirmed that the presence of a chiral center on the N-alkyl substituent may lead to enantiomers which differ in their levels of binding (compounds 54, 57 and 55, 56).
引用
收藏
页码:659 / 667
页数:9
相关论文
共 39 条
[1]   (R)-METHANANDAMIDE - A CHIRAL NOVEL ANANDAMIDE POSSESSING HIGHER POTENCY AND METABOLIC STABILITY [J].
ABADJI, V ;
LIN, SY ;
TAHA, G ;
GRIFFIN, G ;
STEVENSON, LA ;
PERTWEE, RG ;
MAKRIYANNIS, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (12) :1889-1893
[2]  
ADAMS IB, 1995, J PHARMACOL EXP THER, V273, P1172
[3]   PHARMACOLOGICAL AND BEHAVIORAL-EVALUATION OF ALKYLATED ANANDAMIDE ANALOGS [J].
ADAMS, IB ;
RYAN, W ;
SINGER, M ;
RAZDAN, RK ;
COMPTON, DR ;
MARTIN, BR .
LIFE SCIENCES, 1995, 56 (23-24) :2041-2048
[4]   Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides [J].
Barg, J ;
Fride, E ;
Hanus, L ;
Levy, R ;
MatusLeibovitch, N ;
Heldman, E ;
Bayewitch, M ;
Mechoulam, R ;
Vogel, Z .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 287 (02) :145-152
[5]   (-)-Delta(9)-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase [J].
Bayewitch, M ;
Rhee, RH ;
AvidorReiss, T ;
Breuer, A ;
Mechoulam, R ;
Vogel, Z .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (17) :9902-9905
[6]   EFFECTS OF ANANDAMIDE ON CANNABINOID RECEPTORS IN RAT-BRAIN MEMBRANES [J].
CHILDERS, SR ;
SEXTON, T ;
ROY, MB .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (04) :711-715
[7]   RATIONALLY DESIGNED, POTENT COMPETITIVE INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS [J].
COREY, EJ ;
CASHMAN, JR ;
KANTNER, SS ;
WRIGHT, SW .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1984, 106 (05) :1503-1504
[8]   CHEMICAL CHARACTERIZATION OF A FAMILY OF BRAIN LIPIDS THAT INDUCE SLEEP [J].
CRAVATT, BF ;
PROSPEROGARCIA, O ;
SIUZDAK, G ;
GILULA, NB ;
HENRIKSEN, SJ ;
BOGER, DL ;
LERNER, RA .
SCIENCE, 1995, 268 (5216) :1506-1509
[9]   ENZYMATIC-SYNTHESIS AND DEGRADATION OF ANANDAMIDE, A CANNABINOID RECEPTOR AGONIST [J].
DEUTSCH, DG ;
CHIN, SA .
BIOCHEMICAL PHARMACOLOGY, 1993, 46 (05) :791-796
[10]   A NOVEL PROBE FOR THE CANNABINOID RECEPTOR [J].
DEVANE, WA ;
BREUER, A ;
SHESKIN, T ;
JARBE, TUC ;
EISEN, MS ;
MECHOULAM, R .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (11) :2065-2069